Lawrence Jenkins, MD
Urology · New Orleans, LANPI 1376784850
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (28.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Clarus Therapeutics Inc. at 32.6% of the total. Reporting peaked in 2020 at $11,153 and has fallen 86.9% since, to $1,461 in 2025. Among urology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $152.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clarus Therapeutics Inc.$11K
- Endo Pharmaceuticals Inc.$7K
- Coloplast$6K
- Boston Scientific$5K
- Teleflex LLC$1K
- Procept Biorobotics Corporation$802
- plus $2K from 26 others
Across 9 payments — averaging $16,270 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$145K
- Endo USA, Inc.$1K
What the payments were for
- Consulting fees$5,05515%
- Speaking & faculty fees$9,32528%
- Travel & lodging$8,88727%
- Food & beverage$9,36028%
- Education$2681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clarus Therapeutics Inc. | 13 | $10,723 |
| Endo Pharmaceuticals Inc. | 20 | $7,296 |
| Coloplast | 54 | $6,041 |
| Boston Scientific | 61 | $4,831 |
| Teleflex LLC | 10 | $1,313 |
| Procept Biorobotics Corporation | 6 | $802 |
| Endo USA, Inc. | 4 | $334 |
| Progenics Pharmaceuticals, Inc. | 2 | $191 |
| Cook Medical LLC | 2 | $168 |
| Cycle Pharmaceuticals Inc | 1 | $122 |
| Myovant Sciences Inc. | 6 | $118 |
| Axonics, Inc. | 1 | $100 |
| Bayer | 7 | $98 |
| Urogen Pharma, Inc. | 3 | $95 |
| Sanofi | 1 | $79 |
| Dendreon Pharmaceuticals LLC | 4 | $77 |
| KARL Storz Endoscopy-america | 1 | $65 |
| Astellas Pharma US Inc | 3 | $58 |
| Antares Pharma, Inc. | 1 | $50 |
| Merck | 2 | $48 |
| Pfizer | 2 | $35 |
| Urovant Sciences Inc | 2 | $34 |
| Photocure Inc | 1 | $31 |
| Melinta Therapeutics, LLC | 1 | $27 |
| Amgen | 1 | $27 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Laborie Medical Technologies Corp. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Invivyd Inc | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JATENZO$31,714
- XIAFLEX$7,156
- TITAN$4,421
- UroLift System$1,081
- AMS$675
- GreenLight XPS$491
- AMS 700$389
- AQUABEAM SYSTEM$372
- AquaBeam Robotic System$292
- Lumenis Pulse 120H$143
- Venxxiva$122
- Moses 550 D\F\L$117
- GENERAL BPH$106
- PYLARIFY$103
- UPSYLON$103
- Axonics$100
How this compares
$32,894 in reported general payments places this provider in the 90th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 30 | $14,215 |
| MyrbetriqMirabegron | 18 | $12,195 |
| Testosterone Cypionate | 31 | $2,100 |
| Tamsulosin Hcl | 37 | $353 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 16 | $321 |
| Finasteride | 15 | $216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $58 | $12,19518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 199 urology providers in Louisiana.
Other urology in New Orleans
- Richard VanlangendonckNew Orleans$289K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
- Jorge CasoNew Orleans$54K
- Alexis ChesrowNew Orleans$17K
- Joanna TogamiNew Orleans$10K
- Neil BaumNew Orleans$9K
- Kyle RoseNew Orleans$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.